| Q61445511 | A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines |
| Q39938968 | Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks |
| Q30421502 | Advances in the development of universal influenza vaccines |
| Q30416502 | Antibodies against conserved antigens provide opportunities for reform in influenza vaccine design |
| Q39930392 | Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain |
| Q36727549 | Changing perspective on immunization against influenza |
| Q40158436 | Coimmunization with recombinant epitope-expressing baculovirus enhances protective effects of inactivated H5N1 vaccine against heterologous virus |
| Q57093612 | Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection |
| Q30380287 | Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase. |
| Q36785060 | Construction of recombinant baculoviruses expressing hemagglutinin of H5N1 avian influenza and research on the immunogenicity |
| Q37976539 | Correlates of vaccine protection from influenza and its complications |
| Q42230405 | Development of a surveillance scheme for equine influenza in the UK and characterisation of viruses isolated in Europe, Dubai and the USA from 2010-2012. |
| Q30373784 | Development of a vaccine against pandemic influenza viruses: current status and perspectives. |
| Q38017605 | Developments of subunit and VLP vaccines against influenza A virus. |
| Q24615003 | Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses |
| Q30393406 | Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin |
| Q30362744 | Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris. |
| Q42225065 | Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus |
| Q28547305 | Expression and Characterization of Recombinant, Tetrameric and Enzymatically Active Influenza Neuraminidase for the Setup of an Enzyme-Linked Lectin-Based Assay |
| Q42166124 | Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice |
| Q36821869 | Expression of the severe acute respiratory syndrome coronavirus 3a protein and the assembly of coronavirus-like particles in the baculovirus expression system |
| Q36523991 | Genetic evolution of the neuraminidase of influenza A (H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution |
| Q43171890 | In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran |
| Q30375255 | Induction of long-term protective immune responses by influenza H5N1 virus-like particles. |
| Q41378999 | Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. |
| Q30399269 | Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir |
| Q38160083 | Influenza vaccines: from whole virus preparations to recombinant protein technology |
| Q30249879 | Influenza virus neuraminidase (NA): a target for antivirals and vaccines |
| Q36900058 | Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus |
| Q30359683 | Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis. |
| Q54240065 | Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model. |
| Q91925447 | Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus |
| Q57093905 | Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype |
| Q36408162 | Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets |
| Q35235777 | Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses |
| Q35826733 | Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future |
| Q30354478 | Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. |
| Q36739674 | Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin |
| Q84557620 | Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences |
| Q30392305 | Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets |
| Q47548866 | Towards a universal influenza vaccine: different approaches for one goal |
| Q47551663 | Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines |
| Q40102065 | Vaccination with Recombinant Baculovirus Expressing Ranavirus Major Capsid Protein Induces Protective Immunity in Chinese Giant Salamander, Andrias davidianus |
| Q30407657 | Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus |
| Q41712229 | Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens |
| Q36601830 | Vaccines for viral and parasitic diseases produced with baculovirus vectors |
| Q30421558 | Virus-like particles as universal influenza vaccines |
| Q52803898 | WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. |